
Dyronib 70mg Tablet
Marketer
Hetero Healthcare Limited
Salt Composition
Dasatinib (70mg)
Overview Dyronib 70mg Tablet
Chronic myeloid leukemia (CML) is treated with Dyronib 70mg tablets. This medication is prescribed for patients whose CML hasn't responded to other treatments or who experience intolerable side effects from alternative therapies. Dyronib 70mg can be administered with or without food, but consistent daily timing optimizes effectiveness. Dosage and frequency are determined by your physician, based on your condition and may be adjusted. Adhere strictly to your doctor's instructions; incorrect usage or overdosing may lead to severe adverse reactions. Therapeutic benefits may not be apparent for weeks or months; discontinue only under medical supervision. Common side effects include nausea, vomiting, abdominal pain, and skin rash. Increased heart rate and blood pressure fluctuations (high or low) are possible; seek immediate medical attention if these occur. Regular blood pressure monitoring may be implemented. Avoid antacids within two hours of taking Dyronib. The medication can lower blood cell counts, increasing infection risk, necessitating routine blood tests. Inform your healthcare provider of all other medications you're taking, as interactions are possible. Dyronib is contraindicated during pregnancy and breastfeeding. Refrain from driving if dizziness or blurred vision develops.
Uses of Dyronib 70mg Tablet
Chronic myelogenous leukemia
Major Benefits of Dyronib 70mg Tablet:
Follow your doctor's instructions precisely regarding the dosage and treatment length for this medication. Ingest the 70mg Dyronib Tablet whole; avoid chewing, crushing, or breaking it. While it can be taken with or without food, consistency is key—take it at the same time each day.
Common Side effects of Dyronib 70mg Tablet:
- Abdominal pain
- Anemia (low number of red blood cells)
- Breathing problems
- Fatigue
- Fever
- Headache
- Infection
- Low blood platelets
- Musculoskeletal (bone, muscle or joint) pain
- Nausea
- Rash
- Vomiting
How to use Dyronib 70mg Tablet:
Follow your doctor's instructions precisely regarding the dosage and treatment length for this medication. The 70mg Dyronib Tablet should be swallowed whole; do not crush, chew, or divide it. While you can take it with or without food, consistency is key—take it at the same time each day.
How Dyronib 70mg Tablet works:
Oncasin 70mg tablets are a cancer treatment that inhibits the activity of a mutated protein responsible for cancer cell proliferation, thus impeding or retarding tumor growth.
SAFETY ADVICE
AlcoholCONSULT YOUR DOCTOR
The interaction of alcohol with Dyronib 70mg Tablet is currently undefined. Seek medical advice before combining them.
PregnancyCONSULT YOUR DOCTOR
Taking Dyronib 70mg tablets during pregnancy poses a confirmed risk to the unborn child. Therefore, it's inadvisable. Nevertheless, a physician might exceptionally prescribe it in critical circumstances where the potential advantages outweigh the hazards. Always seek medical advice.
Breast feedingUNSAFE
Lactation and the 70mg Dyronib tablet are incompatible; evidence indicates potential infant harm from the medication.
DrivingUNSAFE
Driving ability may be impaired by Dyronib 70mg Tablet side effects. Exercise caution while driving if you experience dizziness or blurred vision after taking Dyronib 70mg Tablet.
KidneySAFE IF PRESCRIBED
Employing Dyronib 70mg tablets in individuals with kidney disease appears to pose minimal risk. Current evidence indicates dose modification for Dyronib 70mg tablets may be unnecessary in such cases. However, physician consultation is recommended.
LiverSAFE IF PRESCRIBED
Dyronib 70mg tablets pose no safety concerns for patients with hepatic impairment; dosage modification is unnecessary.
What if you forget to take Dyronib 70mg Tablet :
Omit any missed Dyronib 70mg Tablet dose and resume your usual medication regimen. Avoid taking a double dose.
Facts to Know About Dyronib 70mg Tablet
| Label | Value |
|---|---|
| Chemical Type | Pyrimidine and Thiazole Derivatives |
| Developing Habits | No. |
| Type of Treatment | Cancer Therapeutics |
| Behavior Class | Kinase inhibitors targeting tyrosine |
